Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.German pharmaceutical firm Grünenthal has signed an exclusive promotion and distribution agreement with MSD covering etoricoxib, a patent-protected, selective COX-2 inhibitor.
Subscribe to our email newsletter
The agreement covers Germany, UK, France, Belgium, Luxemburg, Ireland, and Austria, and etoricoxib is marketed under the brand name of Arcoxia in these markets.
Grünenthal chief commercial officer of Europe, Australia and North America Alberto Grua said Arcoxia is a valuable addition to the company’s product portfolio and strongly contributes to further strengthening its position as a leading player in pain therapy.
"By including Arcoxia into our portfolio in select countries, Grünenthal now also offers an innovative therapy option for the treatment of pain with an inflammatory component, which therefore complements our other existing therapy options for the treatment of nociceptive and mixed nociceptive-neuropathic pain," Grua said.
Main objective of Grünenthal is to become the most patient-centric company in the field of pain and thus to be a leader in therapy innovation.
The company is focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.